Project will use big data and analytics to address pressing public health issue
Bettis unveils new playbook for defending against severe allergic reactions and affected to take action
First patient enrolled in Phase III clinical trial for moxetumomab pasudotox as a treatment for unresponsive or relapsed hairy cell leukemia patients
Simponi has already been approved by the FDA for the treatment of moderately to severely active rheumatoid arthritis
Like a game of whack-a-mole, no matter how many times Johnson & Johnson attempts to put to rest lawsuits over the marketing of its Risperdal...
And so the middle of the week is upon us. Meetings and deadlines loom, no doubt. All the more reason to grab a cup of something stimulating and get caught up on events. Here is to a productive and, hopefully, pleasant day...
Elan Seeks Deals To Raise Cash (Reuters)
Novartis To Focus On Biologics (Bloomberg News)
FDA Gives Mixed Reaction To AstraZeneca Petition (Dow Jones)
UK Strikes Deal To Boost Generic Use (The Financial Times)
Sanofi Settles Patent Dispute With Barr & Teva (Bloomberg News)
